BR112021021384A2 - Métodos e composições para modular splicing de íntrons alternativos - Google Patents
Métodos e composições para modular splicing de íntrons alternativosInfo
- Publication number
- BR112021021384A2 BR112021021384A2 BR112021021384A BR112021021384A BR112021021384A2 BR 112021021384 A2 BR112021021384 A2 BR 112021021384A2 BR 112021021384 A BR112021021384 A BR 112021021384A BR 112021021384 A BR112021021384 A BR 112021021384A BR 112021021384 A2 BR112021021384 A2 BR 112021021384A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- intron splicing
- alternative intron
- modulate alternative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839572P | 2019-04-26 | 2019-04-26 | |
| PCT/US2020/029953 WO2020219977A1 (en) | 2019-04-26 | 2020-04-24 | Methods and compositions for modulating splicing of alternative introns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021384A2 true BR112021021384A2 (pt) | 2021-12-21 |
Family
ID=72941393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021384A BR112021021384A2 (pt) | 2019-04-26 | 2020-04-24 | Métodos e composições para modular splicing de íntrons alternativos |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023348346A1 (en) * | 2022-09-30 | 2025-03-27 | Contera Pharma A/S | Antisense oligonucleotides for the treatment of canavan disease |
| CN121059628A (zh) * | 2024-06-03 | 2025-12-05 | 时夕(广州)生物科技有限公司 | 调控RNA剪接的向导agRNA |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005535318A (ja) * | 2002-08-12 | 2005-11-24 | ユニヴェルシテ ドゥ シェルブルック | プレメッセンジャーrnaのスプライス部位選択の再プログラミング方法 |
| EP3578657B1 (en) * | 2010-04-06 | 2024-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
| WO2015108907A2 (en) * | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| CN107109411B (zh) * | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| WO2017100587A1 (en) * | 2015-12-09 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof |
| CN116059236A (zh) * | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| CA3013683C (en) * | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| SG10201705285SA (en) * | 2017-06-27 | 2019-01-30 | Agency Science Tech & Res | Antisense oligonucleotides |
-
2020
- 2020-04-24 EP EP20795450.4A patent/EP3959313A4/en active Pending
- 2020-04-24 AU AU2020263581A patent/AU2020263581A1/en active Pending
- 2020-04-24 MX MX2021013081A patent/MX2021013081A/es unknown
- 2020-04-24 CN CN202080040348.7A patent/CN114127286A/zh active Pending
- 2020-04-24 BR BR112021021384A patent/BR112021021384A2/pt unknown
- 2020-04-24 JP JP2021563623A patent/JP2022532998A/ja active Pending
- 2020-04-24 KR KR1020217038370A patent/KR20220019676A/ko active Pending
- 2020-04-24 WO PCT/US2020/029953 patent/WO2020219977A1/en not_active Ceased
- 2020-04-24 CA CA3134947A patent/CA3134947A1/en active Pending
-
2021
- 2021-11-03 US US17/518,337 patent/US20220162599A1/en active Pending
-
2025
- 2025-05-27 JP JP2025087686A patent/JP2025128180A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3959313A4 (en) | 2023-09-27 |
| JP2022532998A (ja) | 2022-07-21 |
| AU2020263581A1 (en) | 2021-12-16 |
| KR20220019676A (ko) | 2022-02-17 |
| JP2025128180A (ja) | 2025-09-02 |
| CN114127286A (zh) | 2022-03-01 |
| MX2021013081A (es) | 2021-12-10 |
| CA3134947A1 (en) | 2020-10-29 |
| EP3959313A1 (en) | 2022-03-02 |
| WO2020219977A1 (en) | 2020-10-29 |
| US20220162599A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021021754A2 (pt) | Cicloalquilas substituídas como moduladoras da via de estresse integrada | |
| BR112021021047A2 (pt) | Métodos e composições para modulação de emenda e tradução | |
| AU2016249002B2 (en) | Compositions for modulating C90RF72 expression | |
| MX2020005748A (es) | Metodos y composiciones para modular el empalme. | |
| JOP20210154B1 (ar) | مثبطات kif18a | |
| MX2022002198A (es) | Composiciones y métodos para modular el empalme y la expresión de proteínas. | |
| BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
| BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
| CL2018001897A1 (es) | Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509) | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| BR112020008817B8 (pt) | Compostos moduladores da via de estresse integrada | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| BR112017020895A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| MX2020006072A (es) | Métodos y composiciones relacionados con cpf1 para la edición genica. | |
| BR112018072663A2 (pt) | moduladores da via integrada ao estresse | |
| JOP20210142A1 (ar) | تركيبات rnai لتثبيط التعبير الوراثي عن pnpla3 وطرق استخدامها | |
| BR112016022855A2 (pt) | composições e métodos para modular a expressão de pkk | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR112016028255A2 (pt) | agentes imunorreguladores | |
| MX385822B (es) | Agentes inmunorreguladores. | |
| BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
| MX389437B (es) | Composiciones para modular la expresion de ataxina 2. | |
| EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
| BR112021016056A2 (pt) | Anticorpos de claudina 6 e usos dos mesmos | |
| WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure |